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Abstract
Fragile X Syndrome (FXS) is a genetic disease due to a CGG 
trinucleotide expansion, named full mutation (greater than 200 
CGG repeats), in the FMR1 gene locus Xq27.3; which leads to an 
hypermethylated region in the gene promoter therefore silencing 
it and lowering the expression levels of FMRP, a protein involved 
in synaptic plasticity and maturation.  Individuals with FXS 
present with intellectual disability, autism, hyperactivity, long 
face, large or prominent ears and macroorchidism at puberty 
and thereafter. Most of the young children with FXS will present 
with language delay, sensory hyper arousal and anxiety. Girls 
are less affected than boys, only 25% have intellectual disability. 
Given the genomic features of the syndrome, there are patients 
with a number of triplet repeats between 55 and 200, known 
as premutation (PM) carriers. Most carriers have a normal 
IQ but some have developmental problems. The diagnosis of 
FXS has evolved from karyotype with special culture medium, 
to molecular techniques that are more sensitive and specific 
including PCR and Southern Blot. During the last decade, the 
advances in the knowledge of FXS, has led to the development 
of investigations on pharmaceutical management or targeted 
treatments for FXS. Minocycline and sertraline have shown 
efficacy in children.
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Resumen
El Síndrome de X Frágil  (SXF), es una enfermedad genética 
debida a una expansión del trinucleótido CGG, nombrada 
mutación completa (más de 200 repeticiones de CGG) en el 
gen FMR1, locus Xq27.3; la cual lleva a una hipermetilación 
de la región promotora del gen, silenciándolo y disminuyendo 
los niveles de expresión de la proteína FMRP relacionada con 
la plasticidad y maduración neuronal. Los individuos con SXF 
presentan retardo mental, autismo, hiperactividad, cara alargada, 
orejas grandes o prominentes y macroorquidismo desde la 
pubertad. La mayoría de niños con SXF presentan retraso en 
el lenguaje, hiperactivación sensorial y ansiedad. Las niñas se 
afectan menos que los varones, solo el 25% presenta retardo 
mental. Dadas las características genómicas del síndrome, existen 
pacientes con un número de repetición de la tripleta entre 55 y 
200 que se denominan portadores de la premutación. La mayoría 
de los portadores tienen un coeficiente intelectual normal, pero 
presentan problemas en el desarrollo. El diagnóstico en SXF 
ha evolucionado del cariotipo con medio especial de cultivo, 
a pruebas moleculares más sensibles y específicas incluyendo 
PCR y Southern blot. Durante la última década, los avances en 
el conocimiento sobre el SXF han permitido el desarrollo de 
investigaciones sobre el manejo farmacológico o tratamientos 
específicos para el SXF.  La minociclina y la sertralina han 
demostrado eficacia en niños.
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Introduction  
The Fragile X Syndrome (FXS) is a genetic disease inherited 
through the X chromosome, which was described for the first 
time in 1943 by Martin and Bell1. It is actually considered the 
most common inherited cause of intellectual disability and the 
second most prevalent cause after Down syndrome. Most cases 
of Down syndrome are de novo but FXS is always inherited with 
many individuals in the family tree, either affected or a carrier of 
FXS. Affected men have a classic phenotype characterized by long 
face, large and protruding ears and macroorchidism2. The Fragile 
X Syndrome is caused by an abnormal expansion in the number of 
the trinucleotide CGG repeats located in the 5’ UTR in the fragile X 
mental retardation 1 gene (FMR1) at Xq27.3. It is a dynamic mutation 
with expansion of the CGG repeat in each generation moving from 
the premutation range of 55 to 200 repeats and expanding to a full 
mutation when pass on by a women to her children3.
Patients affected with FXS have more than 200 repeats of the 
CGG trinucleotide. On the other hand, premutation carriers (55 
to 200 repeats) although are not affected with the classic FXS 
phenotype, can have other medical, psychiatric and neurological 
problems. In the last 15 years multiple advances have been made 
in the description of genetic characteristics, function of the 
protein encoded by the FMR1 gene (FMRP), pharmacological 
management and the description, in carriers of the premutation, 
of the Fragile X associated Tremor/Ataxia Syndrome (FXTAS) and 
fragile X-associated primary ovarian insufficiency (FXPOI)3-5.
The objective of this review is to contribute to the dissemination of 
knowledge on FXS among health professionals and thus improving 
the diagnosis and management of these patients. 
1. Epidemiology
The actual worldwide prevalence, determined by molecular 
assays, it’s estimated in one per 5,000 men6 and in one per 4,000 to 
6,000 women6,7. Ricaurte is a district of the municipality of Bolívar, 
located in the north of Valle del Cauca, in which there has been 
identified a high prevalence of mental disability, 39 intellectually 
disable individuals in 1124 habitants8. During the late 1990’s, a 
study found that the cause of this disability in the region was FXS. 
In this study 19 patients were diagnosed with the syndrome by 
karyotype with G bands in folate deficient medium; furthermore 
clinical diagnosis was done in 16 more patients in whom the 
karyotype was not performed. The cases were found in 3 family 
names and a possible common ancestor was postulated given the 
migratory patterns and founding characteristics of the town9. By 
the year 1999 the prevalence of FXS in Ricaurte was determined 
as 1:38 men and 1:100 women, which exceeded 100 times the 
prevalence reported in literature.
A number of medical conditions and syndromes, associated with 
carriers of the premutation including depression, anxiety, migraine 
headaches, hypertension, sleep apnea, immune mediated diseases 
including hypothyroidism and fibromyalgia, and FXTAS and 
FXPOI have been described in the past 10 years10. The prevalence 
of the premutation in the general population is 1:130-200 women 
and 1:250 to 450 men11,12. Tremor/Ataxia Syndrome occurs in 
approximately 40% of men with the premutation and 16% of women, 
whereas FXPOI occurs in approximately 16 to 20% of women with the 
premutation2,10.
2. Genomics
The Fragile X Syndrome is caused by an alteration in the FMR1 
gene, with locus Xq27.3. This gene harbors a CGG repeat within the 
5’ Untranslated Region. Depending on the number of repetitions, 4 
types of alleles are defined with different clinical manifestations3,13: 
Normal alleles, up to 44 CGG repeats; premutation (PM) alleles, 
between 55 and 200 and full mutation alleles (FM) with more 
than 200 repeats. The fourth type of allele is named “grey zone” or 
intermediate allele and contains between 45 and 54 repeats and it 
has been proposed as a precursor for PM alleles. 
The silencing of the FMR1 gene is the result of a series of 
complex epigenetic modifications following the expansion of 
the trinucleotide repeat14. The FM alleles undergo a methylation 
process in the CpG island within the gene promoter and in 
the CGG repeats15,16. In male patients with the FM allele, every 
cytosine within the CpG island is methylated, contrarily to healthy 
individuals who lack of any methylation17. A recently discovered 
boundary sequence in the FMR1 gene found 650 to 800 nucleotides 
upstream from the repeated region that suffers methylation. 
This boundary sequence, because of its chromatin interaction, 
limits the hypermethylated region of the genome, protecting the 
promoter of FMR1 from possible methylation15,16,18. In individuals 
with FXS the methylated boundary sequence is lost allowing the 
expansion of the methylation up to the promoter of the FMR1 
gene. This findings strongly suggest that changes in the sequence 
of nucleotides and conformational structure of the chromatin of 
the boundary sequences would favor the epigenetic changes that 
would induce FMR1 silencing and ultimately preventing FMRP 
production19.
FXS is usually caused by the methylation and gene silencing 
associated with the full mutation although deletions of the coding 
region of the gene can also lead to absence of FMRP. In addition, 
point mutations or reading frame shifts can also occur leading 
to a functional deficit of the protein FMRP and the consequent 
phenotype; however, these genomic changes account only  for less 
than 1% of all FXS cases described20.
The clinical involvement in those with a premutation is caused by 
a different mechanism than FXS, which is elevated FMR1 mRNA 
levels leading to RNA toxicity. 2-8 folds normal levels of mRNA are 
observed in premutation carriers and the excess such mRNA lead 
to the sequestration of important proteins for neuronal function by 
the hairpin structures that form in the CGG repeats. RNA toxicity 
causes the neurons to die earlier in culture and so the carriers are at 
risk for late onset disorders including FXTAS and FXPOI10.
The FMRP is a RNA binding protein that shows preference 
towards RNA homopolymers21 as for certain subgroups of cerebral 
transcripts22.  The protein encoded by the FMR1 gene is involved 
in the regulation of the RNA stability, subcellular transport 
and translation of neural mRNAs that codify for proteins 
involved in the synapsis development, neural plasticity and 
brain development23-25. Various studies have revealed that in the 
absence of this protein, a wide range of neural mRNAs are altered, 
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augmenting neural protein synthesis and resulting in dendritic 
spine  dysmorphogenesis and an excitation/inhibition imbalance 
(Glutamate/GABA), phenomena present in FXS26,27. The dendritic 
spine dysmorphogenesis plays a role in the clinical manifestations 
of the syndrome, due to the weak synaptic connections leading 
to intellectual deficits and behavioral problems. Multiple 
neurotransmitter systems are impaired because of the lack of FMRP 
and there is enhanced protein production in the hippocampus and 
throughout the brain3.  
3. Heritability
FXS heritability does not have a Mendelian classic inheritance 
pattern. It depends on the number of trinucleotide CGG repeats 
within the promoter of the FMR1 gene28. The transition from PM 
to FM alleles occurs because of expansion phenomena during the 
transmission of the maternal X chromosome carrying PM, to her 
children2. This expansion does not occur during the transmission 
of the paternal X chromosome, with the PM, to their daughters 28. So 
all daughters of men with the premutation will be obligate carriers 
of the premutation but then these daughters have a 50% risk to 
have children with FXS. 
3.1. Dynamic of the mutation
The risk of transition from PM to FM in the descendants 
depends on the number of trinucleotide repeats in the PM allele, 
reaching ~100% for PM alleles with more than 99 repeats29,30. The 
expansion from PM to FM in meiosis can occur in alleles with as 
little as 56 CGG repeats31; the odds that this occurs depends on 
the range of repeats in which the patient is classified, number of 
AGG interruptions and age of the mother (Table 1)29,30. Normally 
there is an AGG anchor with every 9 or 10 CGG repeats in FMR1. 
The anchors can modify the risk for expansion of the CGG repeat 
when passed on by the mother. Women with the premutation and 
2 AGG anchors have a lower risk of expansion to the full mutation 
compared to women with no AGG anchors29,30.
The intermediate or grey zone alleles are those that possess 
between 45 and 54 repeats and are proposed as precursors of PM 
alleles. The transition from grey zone alleles to PM alleles occur 
because of paternal or maternal meiosis instability32.
3.2. Inheritance and recurrence risk
Men. The majority of the men with FM usually do not reproduce 
with only 1% of them reported to have offspring2. Male patients 
with FM and FXS have a 100% chance to pass on the premutation to 
their daughters so their daughters will only be carriers and usually 
they do not present with intellectual disabilities. There is loss of 
the FM in the formation of the sperm and only the premutation is 
passed on. All of their sons will receive the Y chromosome so they 
will not be affected with the FMR1 mutation. Meanwhile, men 
with the PM will transmitt only the PM to their daughters and the 
number of repeats is relatively stable2,31.
Women. It’s noteworthy that carriers of the PM can expand their 
allele to FM with odds depending on the number of repeats, 
number of AGG interruptions and age (Table 1). The impact 
of the AGG interruptions is attributed to the decrease of DNA 
polymerase slippage in replication. Therefore, this interruptions 
give stability in the gene’s transmission but does not affect gene’s 
transcription nor translation29,30. 
Besides, according to the newborn’s sex, the clinical characteristics 
are going to differ. Male patients with FM will develop mental 
impairment. On the contrary, daughters who inherit the FM have 
a 30% chance to have a normal intelligence quotient, 25% to have 
intellectual disability with IQ less than 70, nonetheless they can 
present learning deficit (60%) and emotional difficulties (70%)2.
4. Fragile X Syndrome clinical characteristics
The FXS cognitive and emotional phenotype will depend as well 
on the amount of FMRP that is produced, which depends on 
the number of repeats and the methylation degree of the FMR1. 
Range of CGG triplets in the premutated mother Expansion risk to FM depend-ing solely in the number of CGG repeats (%) Age of the mother Expansion risk to FM depending on the CGG repeats and AGG interruptions (%)*0 AGG interruptions 1 AGG interruption 2-3 AGG interruptions55-59       3.7 203040 0.4-1.51.6-6.46.5-23.1 0.1-0.50.5-2.22.3-9.1 00-0.10.1-0.5
60-69       5.3 203040 1.5-22.76.4-56.323.1-85.0   0.5-8.92.2-30.09.1-65.3  0-0.50.1-2.10.5-8.670-79     31.1 203040 22.7-84.756.3-96.085.0-99.1   8.9-64.830.0-89.065.3-97.2   0.5-8.42.1-28.78.6-63.880-89     57.8 203040 84.7-99.096.0-99.899.1-100 64.8-97.289.0-99.397.2-99.8   8.4-63.328.7-88.363.8-97.190-99     80.1 203040 99.0-99.999.8-100100 97.2-99.899.3-10099.8-100 63.3-88.288.3-99.397.1-99.8   >99 100 203040 99.9-100100100 99.8-100100100 88.2-10099.3-10099.8-100* The risk increases within the exposed range as maternal age and CGG repeats increases.
Table 1. Comparison of the expansion risk from premutation to full mutation (FM) between reported percentages depending solely in the number of 
CGG repeats2 and recently reported percentages depending in AGG interruptions and maternal30. 
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ratio of the affected X chromosome AR in peripheral blood (AR= 
percentage or ratio of cells with the normal allele present on active X 
chromosome, so that higher AR correspond to higher FMRP levels 
produced by the normal FMR1 allele). The severity of the phenotype 
in women can vary from typical physical characteristics (Table 2 and 
Fig. 1) and mental impairment to the absence of physical phenotype 
together with a mild learning disability. Seventy per cent of the 
women with the FM present some degree of cognitive impairment2. 
Premutation carriers usually have a normal IQ with mild or no physical 
features; however, approximately 20% of women develop FXPOI or 
FXTAS, although 40% of male carriers develop FXTAS. Tremor/Ataxia 
Syndrome is a late onset progressive neurodegenerative disorder10, 
characterized by neurological deficits that include progressive intention 
tremor, cerebellar ataxia, parkinsonism, neuropathy and autonomic 
dysfunction33-35. Fragile X-associated primary ovarian insufficiency, 
which indicate the cessation of the menses before 40 years old, affects 
women by producing a series of complications in their fertility and 
reproduction, because it causes menstrual cycle irregularities, infertility 
and ovary hormonal deficiency36. 
Depending on the FMRP concentration, a clinical spectrum 
develops. When FMRP levels are not very low the symptoms are 
less severe, there’s a moderate emotional and learning difficulties 
and a normal intelligence quotient. If the production of the FMRP 
protein decreases or stops, a severe cognitive deficit develops 
causing mental impairment2.
Particular physical characteristics also depend and the production 
of FMRP. Thus, the 80% of the patients with FXS will have one 
or more of their common facial characteristics (Table 2 and Fig. 
1)2. The diagnosis is suspected in men with mental impairment, 
particular facial characteristics as long face, large and protruded 
ears, and macroorchidism; this phenotype allows the distinction 
of patients with FXS after puberty to the patients with mental 
impairment and not associated with FXS2,20. However all 
individuals with intellectual disability or autism should have the 
fragile X DNA test because sometimes the physical features are not 
obvious or not present, particularly in young children.
Women with FM and FXS are going to present a wider range of 
phenotypic characteristics than men, depending on the activation 
Characteristics GenderMale Female*
Facial
Large and prominent ears (75-78%) Large and prominent ears (75-78%)Long face Long faceMandibular prognathism (80% adult men) Mandibular prognathism Cleft palate Prominent foreheadMacrocephalyOphthalmologic Strabismus (8%) Strabismus (8%)Refractive errors Refractive errorsInner ear Deafness due to the high recurrence of ear infection
Neurologic Seizures (23%) Seizures (23%)Hypotonia (children) Hypotonia (children)Clonus (adults) Clonus (adults)
Positive palmomental reflex Positive palmomental reflex
Psychiatric 
Poor eye contact Poor eye contact
Attention deficit hyperactivity disorderAnxietyRepetitive motor behaviorAutistic characteristicsAggression and distress crisisDevelopment Mental retardation Mental retardation
Cognitive and language deficit (last one repetitive) Cognitive and language deficit (last one repetitive) 
Orthopedic Flat feetHyper extensibility in the metacarpophalangeal jointScoliosisDouble jointed thumbsThorax Pectus excavatumGenitourinary Macro orchidism (95% of adult men)Cardiovascular Cardiac abnormalities (mitral valve prolapse)Other Obesity, cramped teeth, tall or short stature* The majority of the phenotypic characteristics have been described in males with FXS, women typically have similar features although often less severe.
Table 2. Clinical characteristics of patients with full mutation and Fragile X Syndrome2,21
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repetition and identification of FM and PM patients is possible37,39.
The tests for the diagnosis of FXS must be ordered for patients with 
intellectual disability and/ or autism and additionally any of the 
following features: distinct facial features as large protruded ears, 
long face, among others; family history of intellectual disability, 
autism, macroorchidism (Fig. 2)
Once it is determined that the patient has the FM or PM for 
FXS, DNA molecular testing must be done on all the family 
members that are suspected through the analysis of the pedigree 
of being carriers. Likewise family members with tremor, ataxia, 
neurological symptoms or early ovarian insufficiency would also 
be candidates for the molecular tests40. 
The diagnosis of FXS can be done even in fetus of pregnant carriers 
or patients with FXS using the same molecular tests mentioned 
above (Southern blot and PCR) on chorionic villus sampling40. 
6. Differential diagnosis 
The differential diagnosis includes Sotos syndrome, Prader-Willi 
and Klinefelter as they share particular characteristics. For each 
one of these syndromes there are specific molecular tests that help 
to confirm the diagnosis. These tests will be ordered according 
to the phenotypic findings and clinical analysis of the patients 
(Table 3)2,41,42. The most frequent clinical findings among these 
syndromes that can be contrasted with FXS are: 
•	 Sotos syndrome: intellectual disabilities, tall stature, 
macrocephaly, and epilepsy.
•	 Prader-Willi syndrome: intellectual disabilities, obesity, short 
stature, and hypogenitalism. A subgroup of patients with FXS 
will have a Prader-Willi phenotype but will not have a deletion 
at 15 q11-13 region, although the level of CYFIP protein from 
this region is low.
5. Diagnosis
Initially, the diagnosis of FXS was done through karyotype, which 
allowed the observation of the distal narrowing of the long arm of the X 
chromosome in the band 27.3 (Xq27.3-23.8) using the light microscope. 
The findings of distal constrictions can be done in different chromosomes, 
and are known as fragile sites, from where FXS is named2. 
Nowadays there are several molecular tests available for the 
diagnosis of FXS which are far more sensitive and specific than the 
karyotype11. Besides allowing the diagnosis of patients with the FM 
and FXS, theses tests allow the identification of carriers of the PM, 
which are individuals typically with a normal IQ, but the female 
carriers have a high risk of having children with FXS. As well there 
are molecular tests that allow the quantification of messenger RNA 
(mRNA) and of FMRP protein, allowing a better understanding 
of the physiopathology of the disease by correlating the results 
to the phenotype of the FM and PM patients2. Polymerase chain 
reaction (PCR) and Southern blot are the routine tests for the 
DNA diagnosis of FXS which allow determining the number of 
CGG repeats and the methylation status of the FMR1 gene.
The PCR through the use of specific primers for the FMR1 gene 
allows the amplification of the region that contains the CGG 
repeat and, can identify patients with an expanded FMR1 allele 
particularly in the premutation but also in the full mutation range37.
Usually Southern blot analysis is utilized to better characterize 
alleles in the full mutation range and to determine the methylation 
status38. However, with the new PCR techniques that use double 
primers for a nested PCR, the quantification of CGG triplet 
Figure 1. Description of the typical phenotypic characteristics of Fragile X 
Syndrome.
Figure 2. Use of molecular techniques for Fragile X Syndrome (SXF) diagnosis.
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•	 Klinefelter syndrome: tall stature, hypogenitalism, intellectual 
disabilities (20%)
•	 FRAXE: intellectual disabilities, language impairment, 
hyperactivity, autistic behavior (due to the abnormal repetition 
of CCG triplet in the FMR2 gene)
•	 intellectual disabilities and chromosome fragility in other 
fragile sites have been described (FRAXD and FRAXF genes).
Other less frequent syndromes, with prevalence lower than one 
in 50,000, have similar genetic and physiopathogenic mechanisms 
as well as phenotype to FXS. Among these syndromes there 
are Fragile X syndrome E and Fragile X syndrome F, due to the 
alteration of the FMR2, FAM11A and FRAXD genes respectively. 
If the phenotype of the patient highly suggests FXS and the 
Southern blot results come out negative, molecular testing for 
genes mentioned above should be considered. 
7. Treatment
Multiple studies have been carried out in the attempt to develop 
target treatments for FXS that can improve some of the symptoms 
and the life quality of the affected patient. These investigations 
have had different approaches according to their objectives, 
whether it is the activation of the FMR1 gene or the treatment of 
the symptoms associated to this disease. The mechanism of action 
of some of the medications used focus on epigenetic modulation, 
glutamatergic system and regulation of the translation of FMRP 
target mRNAs (Fig. 3.)
Even though folic acid decreased the observation of fragile sites 
in the X chromosome in in vitro models of FXS, this drug doesn’t 
have the same effect in vivo. Its benefits could derive from the 
role of this micronutrient in the methylation and hydroxylation 
of neurotransmitters, reactions implicated in their synthesis and 
metabolism2. The first clinical trials with this supplement in the 
1980´s reported that folic acid gave a similar positive effect to 
the one obtained with the use of stimulants, specifically in motor 
coordination, language and speech. However, the effectiveness of 
this drug has been difficult to demonstrate in controlled studies, 
limiting its potential as a possible treatment and contraindicating 
it for patients with seizures and FXS2,43.   
Valproic acid, known as a silent gene reactivator3,44, is a weak 
reactivator of the FM alleles in FXS3,45. It has been reported that 
the administration of this drug to patients with FXS improves 
their attention deficit hyperactivity disorder (ADHD). In patients 
Syndromes Mental retardation Stature* Cephalic perimeter* Testicular size* Weight* Diagnostic testsFragile X syndrome Mild to moderate +++ ++ +++ ++/+++ PCR, Southern BlotSotos syndrome Mild to learning problems +++ +++ ++ ++ Sequencing and/or FISH gene NSD1Prader-Willi syndrome Mild to moderate + ++ + +++ FISH 15q11.2-q13Klinefelter syndrome Absent or mild +++ ++ + ++/+++ Karyotype* The following conventions are used:  + Smaller size than general population; ++ Similar size to general population; +++ Bigger size than general population
Table 3. Differential diagnosis of Fragile X Syndrome (2,41,42)
Figure 3. Therapeutic targets and FXS physiopathogenesis. In a neuron with a 
normal range of CGG repeats in the FMR1 gene, there is a euchromatin structural 
conformation which allows the entry of transcription machinery, due to the 
acetylation of histones H3 and H4. This conformation allows the normal production 
of the FMRP, protein that inhibits mRNA translation of some neuronal proteins as 
Neuroligin, NMDA Receptor (NMDAR), AMPA Receptor (AMPAR) and mGluR5 
receptor among others. The expansion above 200 repeats leads to the detection of 
the CpG islands by DNA Methyl-transferases (DNMT) that add methyl groups to 
the cytosines of the CGG sequence and the promoter which silences the gene. This 
methylated cytosines are recognized by the MeCP2 which attracts and activates 
Histone Deacetylases (HDAC) that cleaves acetyl groups from histones H3 and H4 
near the affected segment thus condensing the chromatin. Together, this changes 
silence the gene allowing the excessive production of neuronal proteins causing 
neuronal hyperexcitability, spinal dysmorphogenesis and successive clinical 
manifestations. 5-azadC is a drug that inhibits the DNMT preventing cytosine 
methylation. TSA, butyrate and 4-phenylbutyrate inhibit the HDAC therefore 
acting synergically with 5-azadC. Valproic acid seems to reactivate silenced genes 
but its mechanism has not been yet described. Inhibitors of mGluR5 allows to 
reduce its hyperexcitation, produced by its overproduction, and the consequences 
it carries.
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with generalized tonic-clonic seizures, absence crisis and partial 
seizures this is the drug of choice; as by increasing the levels of 
GABA and decreasing dopamine it is an excellent mood stabilizer 
and can be used in cases of bipolar disorder in adults and even in 
children2,3,46. 
Likewise, L - Acetyl - carnitine also seems to inhibit the formation 
of fragile sites in the X chromosome. Its administration to 
patients with FXS improves significantly their attention deficit 
hyperactivity disorder, however it has no effect in the methylation 
of the FMR1 gene, nor its expression2,3. The use of this drug in 
the treatment of FXS patients could be indicated; however the 
reported studies are not conclusive.
 
The best medications available for treatment of ADHD symptoms in 
FXS are the stimulants including preparations of methylphenidate 
or mixed amphetamine salts. However, these medications should 
not be used in children under age five because they can often cause 
irritability47. Nevertheless, if severe ADHD symptoms occur under 
age five then guanfacine or clonidine can be helpful. Clonidine 
can also be used to treat the sleep disturbance that is a common 
problem for young children with FXS. Alternatively, melatonin at 
a dose of 1 to 3 mg at bedtime works well for facilitating sleep in 
children with FXS48.
The use of mGluR antagonists as 2-methyl-6-phenylethynyl-
pyridine and CTEC, has given as a result the recovery of the 
dendritic spines morphology, protein synthesis, hippocampus 
atrophy and partially the macroorchidism in animal models3,49. 
However, the use of mGluR5 antagonists have not demonstrated 
efficacy in adolescents and adults with FXS in controlled trials2.
One of the great interests and pharmacologic targets for the 
treatment of FXS is the restoration of the FMR1 gene activity by 
decreasing the DNA methylation and altering the H3 and H4 
histones acetylation code. The use of 5-azadC (methyltransferase 
inhibitor) along with histone deacetylase inhibitors like TSA, 
butyrate and 4-phenylbutyrate have been proven to act sinergically 
for this purpose. Both drugs have been tested solely in vitro, due to 
the risk of inducing cellular apoptosis in vivo3.
On the other hand, due the absence of FMRP protein in FXS, 
which regulate synaptic stimulation50, an overproduction of 
metalloproteinase 9 (MMP-9) is produced in response to the 
normal synaptic stimulations in this disease51, which has been 
associated with several pathologic conditions, particularly 
seizures and cerebrovascular accidents52. Active MMP-9 
regulates the pericellular environment through the cleavage of 
protein components. This MMP-9 function has been associated 
with synaptic changes associated with learning and memory53. 
Treatment with minocycline for three months in patients with 
FXS has been proven, in some cases, to decrease MMP-9 activity 
independent of age and doses54.  A controlled trial of minocycline 
(doses 25 to 100 mg per day) in children ages 3.5 to 16 years 
demonstrated efficacy in behavioral improvements and with 
mood and anxiety problems55. 
Minocycline can be used clinically in treatment of children and 
adults with FXS but when used in children under 8 it can lead to 
darkening of the teeth. However, when used in young children it 
may have its greatest effect in strengthening synaptic connections 
and enhancing cognitive development. The physician should 
discuss the side effects of minocycline with the family before 
prescribing Minocycline, which can also lead to loose stools 
usually improving with a probiotic. The darkening of the teeth can 
be fixed cosmetically when the child is older. Rarely minocycline 
can cause elevation of the antinuclear antibody and if a rash or 
swollen joints, visual problems or severe headache occur then 
minocycline should be discontinued55.
Due to the high frequency of mood, anxiety and behavior disorders 
in patients with this syndrome and in carriers of the PM, serotonin 
selective reuptake inhibitors have been used to treat effectively 
aggressive behavior, anxiety, depression among others2. The use 
of sertraline in FXS is a subject of current investigations; articles 
have reported its positive effect in language development in young 
children (2 to 6 years) with FXS among other virtues56. However, 
in about 20% of cases an SSRI can worsen aggression because of 
hyperarousal especially if the dose is high. Therefore, if aggression 
develops with the use of an SSRI, the dose should be lowered 
or discontinued and a mood stabilizer, such as aripiprazole or 
risperidone should be started. Lithium is also an excellent mood 
stabilizer in FXS and a targeted treatment for FXS47. 
Besides all of the pharmacologic options mentioned above, several 
authors, remark on the necessity of developing cognitive and behavior 
therapies, as well as educational and behavioral intervention for these 
patients, to be able to strengthen their social abilities, reading abilities, 
adaptive behavior and support network57-61. Children with FXS are 
also typically very good with the computer so applications that 
focus on language, reading, math, or social deficits can be used 
with the help of the teacher, therapist or parent.
8. Conclusion
In Colombia the prevalence of FXS hasn´t been reported; 
however there are many patients with the full mutation and many 
premutation carriers with an endemic focus in Ricaurte, Valle 
del Cauca. The knowledge of the genomics, physiopathology 
of the disease and the function of the FMRP in the central 
nervous system, the heritability and phenotypical findings in the 
carriers have increased in the last decade. This has allowed the 
stimulation of multiple investigations, especially in pharmacologic 
interventions with targeted treatments that can reverse the 
neurobiology of FXS. However, the drugs that increase the 
FMRP levels or the expression of the FMR1 gene haven´t been 
used in vivo due to safety reasons; other drugs as valproic acid, 
sertraline, minocycline among others, have given good results in 
specific symptoms of FXS patients, although they should be used 
according to each individual response. 
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